← All Absci CORP filings

Absci CORP 10-K annual reports

Annual reports — audited financials, the full risk-factor list, and management’s account of the year.

NASDAQ
ABSI
Absci CORP
10-K: Absci Reports Increased Losses Amidst Clinical Progress
Absci Corporation reported a wider net loss and decreased revenue for 2025, while advancing its lead antibody therapeutic, ABS-201, into clinical trials for androgenetic alopecia and endometriosis.
NASDAQ
ABSI
Absci CORP
10-K: Absci Corporation Reports 2024 Annual Results, Focuses on AI-Driven Drug Creation
Absci Corporation's 2024 10-K filing highlights its focus on AI-driven antibody therapeutics, partnered programs, and internal pipeline development, despite incurring a net loss of $103.1 million.
NASDAQ
ABSI
Absci CORP
10-K: Absci Corporation Implements 2023 Inducement Plan and Outlines Equity Award Terms
Absci Corporation has established a 2023 Inducement Plan to grant equity awards to prospective officers and employees, aiming to align their interests with the company's success.